Insufficient scRNA-seq data for expression of EFNA3 at single-cell level.
Insufficient scRNA-seq data for expression of EFNA3 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
brain | 85% | 1050.59 | 2236 / 2642 | 94% | 10.24 | 662 / 705 |
breast | 41% | 203.52 | 188 / 459 | 96% | 22.37 | 1069 / 1118 |
esophagus | 39% | 835.98 | 564 / 1445 | 92% | 16.67 | 168 / 183 |
intestine | 21% | 97.79 | 200 / 966 | 94% | 25.02 | 498 / 527 |
skin | 72% | 5519.36 | 1305 / 1809 | 42% | 4.21 | 197 / 472 |
ovary | 11% | 42.36 | 19 / 180 | 96% | 11.94 | 411 / 430 |
uterus | 8% | 57.21 | 14 / 170 | 92% | 21.98 | 424 / 459 |
ureter | 0% | 0 | 0 / 0 | 100% | 6.71 | 1 / 1 |
tonsil | 0% | 0 | 0 / 0 | 91% | 11.14 | 41 / 45 |
prostate | 28% | 105.77 | 69 / 245 | 63% | 4.85 | 315 / 502 |
stomach | 1% | 2.10 | 2 / 359 | 86% | 20.53 | 245 / 286 |
lung | 0% | 1.13 | 2 / 578 | 83% | 10.29 | 959 / 1155 |
bladder | 0% | 0 | 0 / 21 | 81% | 12.25 | 407 / 504 |
pancreas | 0% | 0 | 0 / 328 | 80% | 11.98 | 143 / 178 |
adrenal gland | 19% | 64.88 | 48 / 258 | 50% | 11.90 | 116 / 230 |
kidney | 3% | 11.03 | 3 / 89 | 59% | 3.83 | 531 / 901 |
thymus | 1% | 3.79 | 8 / 653 | 58% | 3.74 | 353 / 605 |
liver | 23% | 128.55 | 51 / 226 | 36% | 2.67 | 147 / 406 |
lymph node | 0% | 0 | 0 / 0 | 21% | 0.87 | 6 / 29 |
peripheral blood | 9% | 36.46 | 85 / 929 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 9% | 0.34 | 7 / 80 |
adipose | 3% | 20.16 | 42 / 1204 | 0% | 0 | 0 / 0 |
spleen | 2% | 8.81 | 6 / 241 | 0% | 0 | 0 / 0 |
blood vessel | 1% | 7.92 | 17 / 1335 | 0% | 0 | 0 / 0 |
heart | 0% | 1.35 | 4 / 861 | 0% | 0 | 0 / 0 |
muscle | 0% | 1.29 | 1 / 803 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0045664 | Biological process | regulation of neuron differentiation |
GO_0048013 | Biological process | ephrin receptor signaling pathway |
GO_0007267 | Biological process | cell-cell signaling |
GO_0007411 | Biological process | axon guidance |
GO_1902961 | Biological process | positive regulation of aspartic-type endopeptidase activity involved in amyloid precursor protein catabolic process |
GO_0016525 | Biological process | negative regulation of angiogenesis |
GO_0098552 | Cellular component | side of membrane |
GO_0005886 | Cellular component | plasma membrane |
GO_0005005 | Molecular function | transmembrane-ephrin receptor activity |
GO_0005515 | Molecular function | protein binding |
GO_0046875 | Molecular function | ephrin receptor binding |
Gene name | EFNA3 |
Protein name | Ephrin-A3 (EFL-2) (EHK1 ligand) (EHK1-L) (EPH-related receptor tyrosine kinase ligand 3) (LERK-3) |
Synonyms | LERK3 EFL2 EPLG3 |
Description | FUNCTION: Cell surface GPI-bound ligand for Eph receptors, a family of receptor tyrosine kinases which are crucial for migration, repulsion and adhesion during neuronal, vascular and epithelial development. Binds promiscuously Eph receptors residing on adjacent cells, leading to contact-dependent bidirectional signaling into neighboring cells. The signaling pathway downstream of the receptor is referred to as forward signaling while the signaling pathway downstream of the ephrin ligand is referred to as reverse signaling (By similarity). . |
Accessions | P52797 ENST00000368408.4 [P52797-1] |